1-Year Real-World Outcomes of TAVR With the Fifth-Generation Balloon-Expandable Valve in the United States
TAVR with the S3UR is associated with superior 1-year clinical outcomes and lower gradients than its predecessors, with less PVL and low valve reintervention. Longer follow-up will determine the durability of the RESILIA technology in the SAPIEN valve platform.
Authors
- James T. DeVries (ORCID: https://orcid.org/0000-0003-3920-5831)
- Annapoorna Kini (ORCID: https://orcid.org/0000-0002-7189-3307)
- Ayaz Rahman
- Ricardo Yaryura
- Adam J. Saltzman
- Curtiss Stinis
- Raymond Durkin
- David K. Roberts
- George Petrossian
- Gilbert Tang
Institutions
- Dartmouth–Hitchcock Medical Center (US)
- Mount Sinai Health System (US)
- Sutter Medical Center (US)
- St. Francis Hospital (US)
- Mount Sinai Hospital (US)
- SouthCoast Health (US)
- St. Luke's Hospital (US)
- Sarasota Memorial Hospital (US)
- Scripps Clinic (US)
Publication Details
- Journal
- JACC: Cardiovascular Interventions
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.jcin.2024.11.015
- Citations
- 16
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.43
Funders
- Edwards Lifesciences